FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

397344008: Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality)

    Status: retired, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Mar 2023. Module: SNOMED CT core

    Descriptions:

    Id Description Lang Type Status Case? Module
    1765262011 Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type (morphologic abnormality) en Fully specified name Active Only initial character case insensitive (core metadata concept) SNOMED CT core
    1773087011 Therapy-related acute myeloid leukaemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type en Synonym (core metadata concept) Active Only initial character case insensitive (core metadata concept) SNOMED CT core
    1774373010 Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type en Synonym (core metadata concept) Active Only initial character case insensitive (core metadata concept) SNOMED CT core
    1785804014 Therapy-related AML and myelodysplastic syndrome, topoisomerase type II inhibitor-related type en Synonym (core metadata concept) Active Only initial character case insensitive (core metadata concept) SNOMED CT core

    0 descendants.

    Expanded Value Set

    Outbound Relationships Type Target Active Characteristic Refinability Group Values
    Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type Is a Therapy-related acute myeloid leukemia and myelodysplastic syndrome false Inferred relationship Some
    Inbound Relationships Type Active Source Characteristic Refinability Group
    A subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposide, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukaemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukaemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective haematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement. Associated morphology False Therapy-related acute myeloid leukemia and myelodysplastic syndrome, topoisomerase type II inhibitor-related type Inferred relationship Some 1

    Reference Sets

    Concept inactivation indicator reference set

    GB English

    US English

    SAME AS association reference set (foundation metadata concept)

    Back to Start